Dosage Forms
- 10 mg and 5 mg tablets
Drug Group
Selective agonist for serotonin 5HT1D receptor
Packaging
- 10 tablets in one blister. 3 blisters in a box.
Rizatriptan is indicated for the acute treatment of migraine attacks with or without aura in adults. Rizatriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine.
Selective agonist for serotonin 5HT1D receptor in cranial arteries to cause vasoconstriction and reduce sterile inflammation associated with antidromic neuronal transmission correlating with relief of migraine.
Drinking alcoholic beverages can make headaches worse or cause new headaches to occur. People who suffer from severe headaches should probably avoid alcoholic beverages, especially during a headache. Some people feel drowsy or dizzy during or after a migraine, or after taking rizatriptan to relieve a migraine. As long as you are feeling drowsy or dizzy, do not drive, use machines, or do anything else that could be dangerous if you are dizzy or are not alert.
Serious cardiac events, including some that have been fatal, have occurred following use of 5-HT1 agonists. These events are extremely rare and most have been reported in patients with risk factors predictive of CAD. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation.
Pregnancy category C. There are no adequate and well-controlled studies in pregnant women; therefore, rizatriptan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when rizatriptan is administered to women who are breast-feeding.
Use within 24 hours of another selective 5-HT1 agonist or ergot-containing drug should be avoided due to possible additive vasoconstriction MAO inhibitors and nonselective MAO inhibitors increase concentration of rizatriptan Propranolol: Plasma concentration of rizatriptan increased 70% serotonergic reuptake inhibitors (e.g., SSRIs/SNRIs): Concurrent use of rizatriptan with these agents may increase the risk of serotonin syndrome; monitor. Serotonin agonists (e.g., triptans): Concurrent use of rizatriptan with these agents may increase the risk of serotonin syndrome; monitor.